Dry Eye

Thermamedx, Eyecare Partners to offer EverTears dry eye treatment in 80 markets across the US

ThermaMEDx today announced a partnership with EyeCare Partners to expand EverTears distribution across the network of the national provider of clinically integrated eye care.

Tarsus initiates Phase 2a ERSA trial evaluating TP-03 for treatment of meibomian gland disease

Tarsus Pharmaceuticals has enrolled the first patient in a Phase 2a clinical trial studying TP-03 for the treatment of meibomian gland disease in patients diagnosed with Demodex mites.

Dry eye treatment trends and outlook

Behin Barahimi, MD, discusses some current trends in the treatment of dry eye disease. An oculoplastic, orbital and reconstructive surgeon, she is a member of the faculty at Vanderbilt Eye Institute.

Oyster Point Pharma announces expanded patient access to varenicline solution

July 28, 2022

Oyster Point Pharma Inc. this week announced the expansion of patient access to varenicline solution (Tyrvaya) nasal spray and provided an update on the commercial performance of the spray in the United States. According to the company, its expanded patient access programs include more eligible patients with dry eye disease.

RegeneRx licensee to expand Phase 3 clinical trial program with RGN-259

June 24, 2022

RegeneRx Biopharmaceuticals Inc. said its U.S. joint venture partner and licensee, HLB Therapeutics, will expand its ophthalmic clinical development program with RGN-259 in two indications, neurotrophic keratopathy and dry eye disease.